Project Grant R41AI195239
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $303K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Eno Valley, NC 27712, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), with a CFDA number of 93.855, provides $314,347 in funding to Gateway Bio Inc. for the period from September 23, 2025 to August 31, 2026. The project aims to develop a new lipid nanoparticle (LNP) delivery system for mRNA payloads that uses a proprietary polyethylene glycol (PEG) alternative called POEGMA. This novel LNP is intended to address concerns around PEG-related allergies and reduced...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $108,486 to the Scripps Research Institute to develop soluble and membrane-bound immunogens that can shepherd the maturation of broadly neutralizing antibodies (bnAbs) targeting the highly conserved membrane proximal external region (MPER) of the HIV-1 envelope protein. The goal is to advance the quest for a...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,017,032 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the Scripps Research Institute. The grant supports research to develop a single-shot sequential immunization regimen for HIV using atomic layer deposition (ALD) technology. The project aims to create a vaccine capable of eliciting broadly neutralizing antibodies (bNAbs) to provide effective protection...
- This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the dynamics and evolution of HIV Gag and GagPol processing. The $752,745 award aims to use molecular dynamics simulations, single-molecule FRET imaging, and cryo-electron tomography to probe the structure and dynamics of Gag and GagPol that enable ordered processing by the viral...
- The University of Pennsylvania received a $891,410 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on therapeutic vaccination strategies to boost autologous neutralizing antibodies for ART-free HIV control. The award is focused on testing whether individualized mRNA-LNP delivered Env immunogens can enhance baseline autologous neutralizing antibody responses...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $919,501 to Emmune Inc. to develop a non-viral gene therapy platform using ECD4-IG, an antibody-like therapeutic protein, to suppress HIV replication for a lifetime after a single intramuscular injection. The goal is to achieve a functional cure for HIV by sustaining therapeutically-effective plasma...